Lymphoma, Solid Tumor
Conditions
Keywords
PRMT5
Brief summary
The primary objective of Phase I of this study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CTS3497 in patients with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas. The primary objective of Phase II of this study is to evaluate the efficacy of CTS3497 in patients with metastatic or locally advanced MTAP-deficient solid tumors and lymphomas.
Detailed description
The primary objective of Phase I of this study is to evaluate the safety, tolerability, PK, PD and efficacy to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CTS3497 in patients with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas. The primary objective of Phase II of this study is to evaluate the efficacy and safety of CTS3497 in patients with metastatic or locally advanced MTAP-deficient solid tumors and lymphomas.
Interventions
DRUGCTS3497
CTS3497: Orally via capsules
Sponsors
CytosinLab Therapeutics Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥ 18 years of age at the signing of ICF. * Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors who cannot be treated surgically and have failed standard of care (SoC). Or patients with refractory/relapsed lymphomas. * MTAP deficiency is confirmed by IHC or NGS. * At least one evaluable tumor lesion at screening for patients in escalation part, and at least one measurable tumor lesion for patients in expansion part. * ECOG performance status of 0 to 1. * Adequate hematopoietic function, cardiac function, liver function, renal function, and coagulation function per local laboratory.
Exclusion criteria
* Female patients in pregnancy or lactation. * Patients with dysphagia; or a condition that seriously affects gastrointestinal absorption. * Allergic or intolerant to the active ingredients or excipients of the investigational product. * Anti-tumor therapy within 28 days of study day 1. * Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor. * Central nervous system (CNS) metastasis at screening. * Live vaccine therapy within 4 weeks before study drug administration. * Use of therapeutic anti-coagulation for treatment of active thromboembolic events. * Use of prescription medications that are known strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4) within 14 days or 5 half-lives (whichever is longer) before study day 1. * Unresolved toxicity from prior anti-cancer therapy. * Active infection of HIV, HBV or HCV. * Patients who are judged by the investigator to have a history of other serious systemic diseases, or not suitable for participating in the trial for any other reason.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase I: Number of Patients Who Experience a Dose-Limiting Toxicity (DLT) | Up to 21 days after the first administration. | Incidence of DLT(s) during the DLT observation period |
| Phase I: Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE) | Baseline through 28 days after the end of treatment, estimated up to 52 weeks. | Adverse events (AEs) are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests will be recorded as TEAEs. Serious AEs (SAEs) are defined as any event that meets at least 1 of the following criteria: resulting in death (fatal); requiring in-patient hospitalization or prolongation of existing hospitalization; resulting in persistent or significant disability/incapacity; being a congenital anomaly/birth defect; other medically important serious event. |
| Phase II: Objective Response Rate (ORR) | up to 48 weeks. | The percentage of participants having complete response (CR) or partial response (PR) assessed based on RECIST V1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) | up to 48 weeks. | Disease Control Rate assessed by investigators based on RECIST v1.1 |
| Duration of Response (DoR) | Estimated up to 48 weeks. | Duration of response (DOR) assessed based on the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1. |
| Progression-Free Survival (PFS) | Estimated up to 48 weeks. | Progression-Free Survival assessed by investigators based RECIST v1.1 |
| Cmax of CTS3497 | Cycle 1 (each cycle is 21 days) Day 1, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 5 Day 1 | Maximal Plasma Concentration |
| Pharmacodynamic (PD) characteristics of CTS3497: symmetric dimethylarginine (SDMA) | Cycle 1 (each cycle is 21 days) Day 1, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 5 Day 1 and Cycle 7 Day 1 | To explore the changes of symmetric dimethylarginine (SDMA) in blood of patients with solid tumors and lymphomas before and after administration of CTS3497. |
| Pharmacodynamic (PD) characteristics and efficacy analysis. | Estimated up to 48 weeks. | The correlation between the changes of symmetric dimethylarginine (SDMA) in blood of patients and the efficacy of CTS3497 |
| Overall Survival (OS) | Up to approximately 3 years. | Overall Survival after first dose |
| Tmax of CTS3497 | Cycle 1 (each cycle is 21 days) Day 1, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 5 Day 1 | Time to Achieve Maximal Plasma Concentration |
| AUC of CTS3497 | Cycle 1 (each cycle is 21 days) Day 1, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 5 Day 1 | Area Under the Plasma Concentration Versus Time Curve |
Countries
China
Contacts
Primary ContactShuning Xing, MS
Backup ContactJifang Gong, MD
Outcome results
None listed